首页> 外文期刊>Methods: A Companion to Methods in Enzymology >Quantification of serum apolipoproteins A-I and B-100 in clinical samples using an automated SISCAPA-MALDI-TOF-MS workflow
【24h】

Quantification of serum apolipoproteins A-I and B-100 in clinical samples using an automated SISCAPA-MALDI-TOF-MS workflow

机译:使用自动SISCAPA-MALDI-TOF-MS工作流程对临床样品中的血清载脂蛋白A-I和B-100进行定量

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A fully automated workflow was developed and validated for simultaneous quantification of the cardiovascular disease risk markers apolipoproteins A-I (apoA-I) and B-100 (apoB-100) in clinical sera. By coupling of stable-isotope standards and capture by anti-peptide antibodies (SISCAPA) for enrichment of proteotypic peptides from serum digests to matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS detection, the standardized platform enabled rapid, liquid chromatography-free quantification at a relatively high throughput of 96 samples in 12 h. The average imprecision in normo- and triglyceridemic serum pools was 3.8% for apoA-I and 4.2% for apoB-100 (4 replicates over 5 days). If stored properly, the MALDI target containing enriched apoA-1 and apoB-100 peptides could be re-analyzed without any effect on bias or imprecision for at least 7 days after initial analysis. Validation of the workflow revealed excellent linearity for daily calibration with external, serum-based calibrators (R-2 of 0.984 for apoA-I and 0.976 for apoB-100 as average over five days), and absence of matrix effects or interference from triglycerides, protein content, hemolysates, or bilirubins. Quantification of apoA-I in 93 normo- and hypertriglyceridemic clinical sera showed good agreement with immunoturbidimetric analysis (slope = 1.01, R-2 = 0.95, mean bias = 4.0%). Measurement of apoB-100 in the same clinical sera using both methods, however, revealed several outliers in SISCAPA MALDI-TOF-MS measurements, possibly as a result of the lower MALDI-TOF-MS signal intensity (slope = 1.09, R-2 = 0.91, mean bias = 2.0%). The combination of analytical performance, rapid cycle time and automation potential validate the SISCAPA MALDI-TOF-MS platform as a valuable approach for standardized and high-throughput quantification of apoA-I and apoB-100 in large sample cohorts. (C) 2015 Elsevier Inc. All rights reserved.
机译:开发并验证了全自动工作流程,用于同时定量临床血清中心血管疾病风险标志物载脂蛋白A-I(apoA-I)和B-100(apoB-100)。通过将稳定同位素标准品与抗肽抗体(SISCAPA)结合以从血清消化物中富集蛋白质型肽到基质辅助激光解吸/电离飞行时间(MALDI-TOF)MS检测,该标准化平台得以实现在12小时内以96个样品的相对较高通量进行快速,无液相色谱的定量分析。正常和甘油三酸酯血清库中的平均不精密度对于apoA-I为3.8%,对于apoB-100为4.2%(5天重复4次)。如果正确存储,则可以在最初分析后至少7天重新分析含有丰富的apoA-1和apoB-100肽的MALDI靶标,而不会对偏倚或不精确产生任何影响。工作流程的验证表明,使用外部基于血清的校准剂进行日常校准具有出色的线性度(R-2的apoA-I的R-2为0.984,apoB-100的R-2为五天的平均值),并且没有基质效应或甘油三酸酯的干扰,蛋白质含量,溶血产物或胆红素。 93正常和高甘油三酯血症的临床血清中apoA-I的定量与免疫比浊分析显示出很好的一致性(斜率= 1.01,R-2 = 0.95,平均偏差= 4.0%)。但是,使用两种方法对同一临床血清中的apoB-100进行测量时,发现SISCAPA MALDI-TOF-MS测量中存在多个异常值,这可能是由于MALDI-TOF-MS信号强度较低(斜率= 1.09,R-2 = 0.91,平均偏差= 2.0%)。分析性能,快速的循环时间和自动化的潜力相结合,验证了SISCAPA MALDI-TOF-MS平台是在大样本人群中对apoA-I和apoB-100进行标准化和高通量定量的一种有价值的方法。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号